Subcutaneous etanercept rapidly alleviated pain and inflammation in 12 acute gout patients compared to methylprednisolone.

This single-center, prospective, randomized, open-label study investigated the efficacy of subcutaneous etanercept in treating acute gout flares. The intervention involved administering 25 mg of etanercept twice over five days. This was compared against a control group receiving 20 mg of methylprednisolone intravenously daily for the same five-day period. The study population consisted of 12 patients with acute gout.

The primary outcome measured was the alleviation of pain and inflammatory responses. Results indicated that all 12 patients (12/12) experienced rapid and substantial alleviation of symptoms. Secondary outcomes included C-reactive protein (CRP) levels and Visual Analog Scale (VAS) scores. The overall effect of etanercept was described as comparable to that of methylprednisolone.

Safety and tolerability were monitored throughout the study period. Adverse events were diligently recorded, but no serious adverse events, discontinuations, or specific tolerability issues were reported. The follow-up duration was five days.

Key limitations include the very small sample size of 12 patients and the single-center setting, which restrict the generalizability of the results. Consequently, while etanercept might be contemplated for off-label use in patients who do not respond to standard therapy or encounter severe side effects and contraindications, further research is needed to confirm these findings.